Working... Menu
Trial record 1 of 1 for:    tocilizumab | Type 1 Diabetes
Previous Study | Return to List | Next Study

Tocilizumab (TCZ) in New-onset Type 1 Diabetes (EXTEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02293837
Recruitment Status : Active, not recruiting
First Posted : November 18, 2014
Last Update Posted : May 3, 2019
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : August 2019
  Estimated Study Completion Date : August 2020